April 9, 2014 09:59 UTC

Research and Markets: PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/tbtbm7/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

Similar to the situation in the UK, sales in the Japanese market are severely constrained by the absence of a routine HBV immunization program. Furthermore, Japan also does not target adult risk groups for HBV immunization, an approach that is unique among the eight markets discussed in this report. While Japanese policymakers have hinted at a more pro-vaccine stance, GlobalData does not expect HBV immunization recommendations to be expanded in Japan during the forecast period, which poses a serious barrier to market growth.


  • Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Hepatitis B disease market.

Key Topics Covered:

  1. Tables & Figures
  2. Introduction
  3. Disease Overview
  4. Vaccination Recommendations and Coverage Rates
  5. Competitive Assessment
  6. Opportunity and Unmet Need
  7. Market Outlook
  8. Appendix

Companies Mentioned

  • Recombivax HB
  • Bimmugen

For more information visit http://www.researchandmarkets.com/research/tbtbm7/pharmapoint


Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Source: Research and Markets